Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on July 31, 2026, and financial results for the quarter ended June 30, 2026. Health Catalyst, Inc. (HCAT) is a Delaware corporation reporting on the completion of a material asset disposition and the subsequent termination of a credit facility.
Key Financial Metrics and Transactions
- Asset Disposition: Completed the sale of all equity interests in VitalWare, LLC to Med-Metrix, LLC for an aggregate base purchase price of $147 million, subject to customary adjustments.
- Debt Repayment: Voluntarily repaid in full all outstanding obligations under its Credit Facility using net proceeds from the VitalWare sale and cash on hand.
- Debt Components Repaid:
- Initial term loan principal: $122,812,500
- Delayed draw facility principal: $37,134,500
- Prepayment premium: $3,198,940
- Accrued and unpaid interest: $548,022
- Liquidity Impact: The repayment resulted in the termination of the Credit Facility and the release of all associated liens.
Material Changes Versus Prior Period
The filing does not provide specific comparative revenue, profit, or margin data for the quarter ended June 30, 2026, as the detailed financial results are contained in a press release (Exhibit 99.1) incorporated by reference but not included in the text of this filing. The primary material change is the removal of the VitalWare business segment and the elimination of approximately $160 million in debt obligations (principal plus premium and interest) that were previously scheduled to mature on July 16, 2029.
Outlook, Risks, and Unusual Items
- Transition Services: Health Catalyst entered into a transition services agreement to provide support to the buyer for up to six months following the closing.
- Pro Forma Information: Unaudited pro forma financial statements reflecting the disposition are filed as Exhibit 99.3. These are not intended to represent future results.
- Regulatory Disclosure: The financial results and disposition announcement are furnished under Regulation FD and are not deemed "filed" for Section 18 liability purposes under the Exchange Act.
Investor Verification Checklist
- Verify the final purchase price of the VitalWare disposition after customary adjustments for cash, indebtedness, and working capital.
- Review the attached press release (Exhibit 99.1) for specific Q2 2026 revenue, net income, and cash flow figures.
- Examine the unaudited pro forma financial statements (Exhibit 99.3) to understand the projected financial position post-disposition.
- Confirm the terms of the transition services agreement to assess any ongoing operational costs or revenue recognition impacts.